Pharmaceuticals

Sarcoidosis Drug Market Forecast: How Big Will It Be by 2030?

February 18, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the sarcoidosis drug market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Sarcoidosis Drug Market in 2026, and what figure is it projected to hit by 2030?

The sarcoidosis drug market has witnessed substantial growth in recent years. It is projected to expand from $7.88 billion in 2025 to $8.42 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.8%. This historic expansion can be ascribed to progress in genomic research, a decrease in sequencing expenditures, the proliferation of academic research, an uptick in diagnostic testing, and pharmaceutical R&D investments.

The sarcoidosis drug market size is anticipated to undergo robust development over the next few years. This sector is projected to reach $10.98 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.9%. The expansion foreseen in this period stems from factors such as the integration of personalized medicine, an increase in companion diagnostics, AI-enabled genomics, escalating demand from pharmaceutical firms, and government initiatives in genomics. Key trends for the forecast duration encompass the broadened application of precision medicine, the growing adoption of cfdna and liquid biopsy, advanced high-throughput genotyping technologies, the incorporation of AI-based data analysis, and the progression of pharmacogenomics.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24392&type=smp

Which Drivers Are Affecting Market Participation In The Sarcoidosis Drug Market?

The rising volume of clinical trials is projected to fuel the expansion of the sarcoidosis drug market moving ahead. These trials represent human research investigations designed to assess the safety, efficacy, and adverse reactions associated with medical therapies or procedures. The escalation in clinical trials stems from a heightened need for tailored and novel therapies, which necessitate stringent safety and effectiveness evaluations. Within clinical trials, sarcoidosis drugs are employed to gauge their effectiveness, safety profiles, and influence on disease advancement, with the objective of enhancing patient results and discovering superior treatment options. As an illustration, in December 2024, data from the Association of the British Pharmaceutical Industry, a pharmaceutical industry trade organization situated in the UK, indicated that the aggregate count of industry-funded clinical trials commenced in the United Kingdom rose from 411 in 2022 to 426 in 2023. Concurrently, Phase III trial commencements expanded by 16.5 percent during the identical timeframe, moving from 182 to 212. Consequently, the expanding volume of clinical trials is propelling the market for sarcoidosis drugs forward.

What Segment Categories Are Covered In The Sarcoidosis Drug Market?

The sarcoidosis drug market covered in this report is segmented –

1) By Type: Ocular Sarcoidosis, Neurosarcoidosis, Cardiac Sarcoidosis, Musculoskeletal Sarcoidosis, Cutaneous Sarcoidosis, Renal Sarcoidosis, Hepatic Sarcoidosis, Sarcoidosis Of The Spleen and Bone Marrow, Pulmonary Sarcoidosis

2) By Mechanism of Action: Corticosteroid, Immunosuppressants, Antimalarial, Tumor Necrosis Factor-alpha (TNF-Alpha) Inhibitors

3) By Indication: Lung Involvement, Skin Involvement, Cardiac Involvement, Neurological Involvement

4) By Route of Administration: Oral, Intravenous, Topical

5) By End User: Hospitals And Clinics, Surgical Centers, Diagnostic Centers, Other End Users

Subsegments:

1) By Ocular Sarcoidosis: Anterior uveitis, Posterior uveitis, Panuveitis, Conjunctival sarcoidosis

2) By Neurosarcoidosis: Cranial neuropathy, Meningeal involvement, Spinal cord sarcoidosis, Peripheral neuropathy

3) By Cardiac Sarcoidosis: Arrhythmias, Heart block, Cardiomyopathy, Heart failure

4) By Musculoskeletal Sarcoidosis: Arthropathy, Myopathy, Bone lesions, Sarcoid arthritis

5) By Cutaneous Sarcoidosis: Lupus pernio, Erythema nodosum, Maculopapular lesions, Scar sarcoidosis

6) By Renal Sarcoidosis: Granulomatous interstitial nephritis, Nephrocalcinosis, Hypercalciuria, Tubulointerstitial nephritis

7) By Hepatic Sarcoidosis: Granulomatous hepatitis, Hepatomegaly, Cholestasis, Portal hypertension

8) By Sarcoidosis Of The Spleen And Bone Marrow: Splenomegaly, Hypersplenism, Bone marrow infiltration, Pancytopenia

9) By Pulmonary Sarcoidosis: Hilar lymphadenopathy, Interstitial lung disease, Fibrotic sarcoidosis, Bronchial obstruction

Which Trends Are Expected To Influence The Sarcoidosis Drug Market In The Upcoming Years?

Leading companies within the sarcoidosis drug market are focused on developing cutting-edge solutions, such as anti-TNFα monoclonal antibodies, to manage treatment-resistant cases and enhance patient outcomes. These anti-TNFα monoclonal antibodies are biologic medications designed to inhibit tumor necrosis factor-alpha (TNFα), thereby reducing inflammation and tissue damage in conditions like sarcoidosis and other autoimmune diseases. For instance, in November 2023, Xentria Inc., a US-based pharmaceutical company, received an orphan drug designation from the European Medicines Agency (EMA) for XTMAB-16, intended to treat sarcoidosis. XTMAB-16 is a chimeric human-murine monoclonal antibody engineered to specifically target and block tumor necrosis factor alpha (TNFα), a crucial inflammatory molecule implicated in the formation of granulomas characteristic of sarcoidosis. It aims to disrupt the inflammatory pathway and potentially slow the progression of granuloma formation in patients with sarcoidosis, particularly pulmonary sarcoidosis, which affects the lungs.

Which Major Firms Are Strengthening Their Position In The Sarcoidosis Drug Market?

Major companies operating in the sarcoidosis drug market are AbbVie Inc., Novartis AG., Viatris Inc., Boehringer Ingelheim International GmbH, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Mallinckrodt plc, Kyorin Pharmaceutical Co. Ltd., Molecure S.A., aTyr Pharma Inc., Xentria Inc., Relief Therapeutics Holding AG, Foresee Pharmaceuticals Co. Ltd., OrphAI Therapeutics Inc., Bellus Health Inc., AI Therapeutics Inc., Araim Pharmaceuticals Inc., Kinevant Sciences GmbH, SarcoMed USA Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/sarcoidosis-drug-global-market-report

Which Region Shows The Strongest Potential For Future Expansion In The Sarcoidosis Drug Market?

North America was the largest region in the sarcoidosis drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sarcoidosis drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Sarcoidosis Drug Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24392&type=smp

Browse Through More Reports Similar to the Global Sarcoidosis Drug Market 2026, By The Business Research Company

Sarcoma Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/sarcoma-drugs-global-market-report

Anticoccidial Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anticoccidial-drugs-global-market-report

Lung Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795